Clinical trials: Treatment Resistant Depressive Disorder
Treatment Resistant Depression
Structural and Functional Connectivity of Brainstem Monoamine Pathways in Treatment Resistant Depression
Study TRD subjects' resistance to at least 2 different antidepressants, we hypothesize that because of their significant depression and treatment resistant status they are most likely to exhibit BSMN pathway abnormalities.
- Trial name
- MAOI (NCT03109717)
- Testing
- Monoamine Oxidase Inhibitor (MAOI)
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Kathryn O'Connor
Depression
A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression
The purpose of this study is to explore feasibility of combining clinician-directed cognitive behavioral therapy (CBT) supplemented with the Mindset app with esketamine therapy in participants with Treatment-resistant Depression.
- Trial name
- NCT05268497
- Testing
- Esketamine, Cognitive Behavioral Therapy (CBT), Antidepressant
- Where
- 5 sites in United States
- Sponsor
- Janssen Research & Development, LLC
Treatment Resistant Depression
Epidural Cortical Stimulation for Depression
Objective: Chronic epidural cortical stimulation (ECS) involves the neurosurgical placement of an electric wire on the surface of the brain with intermittent activation.
- Trial name
- EpCS-D (NCT00565617)
- Testing
- Synergy, Epidural cortical stimulation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Medical University of South Carolina
Treatment Resistant Depression, Substance Use Disorders
Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder
The goal of this clinical trial is to learn if a single dose of psilocybin (5mg Vs 10mg Vs 25mg) alongside psychotherapy is safe and can help treat treatment resistant depression (TRD) with co-occurring substance use disorder…
- Trial name
- NCT07499583
- Testing
- Psilocybin
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Indiana University
Depressive Disorder, Treatment-Resistant
Clinical Trial of the Use of Ketamine in Treatment Resistant Depression
The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission and inflammatory…
- Trial name
- NCT02610712
- Testing
- Ketamine
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- National Institute of Neurology and Neurosurgery, Mexico
Treatment-resistant Depression (TRD)
Esketamine With or Without Integration Therapy for Treatment-Resistant Depression
This study will explore the effects of esketamine (Spravato®), an FDA-approved nasal spray, on adults diagnosed with treatment-resistant depression (TRD).
- Trial name
- KIND-PR (NCT07369102)
- Testing
- Esketamine hydrochloride (intranasal), Integration Therapy
- Where
- 2 sites in Puerto Rico
- Volunteers
- 20 people
- Sponsor
- University of Puerto Rico
Major Depression
Magnetic Seizure Therapy (MST) for Treatment Resistant Major Depression
The investigators intend to test in a single center, clinical pilot efficacy study the primary hypothesis that Magnetic Seizure Therapy (MST) as add-on therapy to a controlled pharmacotherapy is efficacious in the treatment of…
- Trial name
- NCT00770783
- Testing
- Thymatron, Tonica MagPro MST
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital, Bonn
Treatment-resistant Bipolar Depression
Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression
The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment…
- Trial name
- NCT03522545
- Testing
- Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center, Houston
Treatment-resistant Depression
Olfactory and Brain Stimulations in Treatment-resistant Depression
This is a prospective, randomized, double-blind, parallel-group controlled trial. The aim of this research project is to compare the clinical benefits achieved in patients with major depressive disorder (MDD) following two types…
- Trial name
- COBRA (NCT05661383)
- Testing
- Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) combined with pleasant odors delivered during the iTBS procol., Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) delivered alone.
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Hôpital le Vinatier
Depressive Disorder, Treatment-Resistant
Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression
The main objective of the study will be to evaluate the effectiveness of an adjuvant lifestyle-based intervention for treatment-resistant patients with major depressive disorder.
- Trial name
- NCT04428099
- Testing
- Lifestyle change promotion program, Mindfullness based cognitive program, Written Information
- Where
- Spain
- Volunteers
- 186 people
- Sponsor
- University of the Balearic Islands
Treatment Resistant Depression
Pharmacogenomics for Antidepressant Guidance and Education
More than one out of three individuals treated for major depressive disorder (MDD) do not experience a full reduction of symptoms even when treated with adequate antidepressant medication.
- Trial name
- NCT01555021
- Testing
- Genotyping assays
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Massachusetts General Hospital
Post-Traumatic Stress Disorders, Major Depressive Disorder
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
Co-occurring post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) is the most common response to trauma; it is associated with poor clinical outcomes and substantial human disability.
- Trial name
- NCT04032301
- Testing
- Ketamine, Normal Saline
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Bipolar Depression
Effect of Intermittent ThetaBurst Stimulation in Treatment-resistant Bipolar Depression
The aim is to evaluate the evaluate the clinical interest and the safety of repetitive transcranial magnetic stimulation (rTMS) delivered as intermittent Theta burst stimulation(iTBS) on severity of depression in patients with…
- Trial name
- iTBS-BIP (NCT02740244)
- Testing
- active iTBS
- Volunteers
- 20 people
- Sponsor
- Hôpital le Vinatier
Treatment Resistant Depression
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression: OL Cohort
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- SAINT-TRD (NCT03240692)
- Testing
- Accelerated theta-burst stimulation treatment
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Stanford University
Depression, Treatment Resistant Depression
Computational Psychiatric Approach to Depression
The purpose of this research is to investigate how the brain changes in patients undergoing electroconvulsive (ECT) treatment for depression.
- Trial name
- NCT04189939
- Testing
- clinical assessments
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Major Depressive Disorder
Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone
Major depressive disorder (MDD) is highly prevalent and nearly 70% of individuals with MDD do not respond to standard antidepressant therapies despite adequate dosing.
- Trial name
- NCT02900092
- Testing
- Ganaxolone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
The purpose of this study is to evaluate how well each individual dose of esketamine (56 milligrams [mg] and 84 mg) works when compared with placebo in improving depressive symptoms in participants with treatment resistant…
- Trial name
- NCT07716098
- Testing
- Esketamine 56 mg, Esketamine 84 mg
- Where
- 39 sites in United States, China and 2 more
- Volunteers
- 348 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder, Treatment-Resistant Depression
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a common, chronic mental illness. It can take weeks to months for antidepressants to work. Researchers want to test a new drug that might act more rapidly.
- Conditions
- Major Depressive Disorder, Treatment-Resistant Depression, Depression
- Trial name
- NCT04821271
- Testing
- TS-161
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Mental Health (NIMH)
Suicidal Ideation, Treatment-resistant Depression
Cortical Inhibition as a Biomarker of Response in a Comparison of Bilateral Versus Unilateral Accelerated Theta Burst Stimulation for Suicidal Ideation in Treatment-Resistant Depression -COMBAT-SI
This is a prospective clinical trial to confirm the effectiveness of bilateral accelerated theta burst stimulation (aTBS) on suicidal ideation (SI), while exploring cortical inhibition measures in this treatment paradigm.
- Trial name
- COMBAT-SI (NCT05377177)
- Testing
- Accelerated Theta Burst Stimulation
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of California, San Diego
Depressive Disorder, Major
A Clinical Trial for the Treatment of Depression With Repetitive Transcranial Magnetic Stimulation (rTMS)
The purpose of this study is to determine whether the Cervel Neurotech rTMS device is safe and effective in the treatment of depression in people who do not get better with antidepressant medications or cannot take antidepressant…
- Trial name
- NCT01909232
- Testing
- Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator, Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
- Where
- 6 sites in United States
- Volunteers
- 92 people
- Sponsor
- Cervel Neurotech, Inc.